Format

Send to

Choose Destination
Gan To Kagaku Ryoho. 2002 Oct;29(10):1759-63.

[Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination].

[Article in Japanese]

Author information

1
Division of Cancer Medicine, Graduate School of Medicine, Kanazawa University.

Abstract

This study was designed to evaluate the pharmacokinetics and toxicity of docetaxel administered via an intraperitoneal (i.p.) route for patients with gastric cancer. Eleven patients with peritoneal dissemination were entered into this trial. Patients were treated with 45 mg/m2 of i.p. docetaxel administration in 1 l of saline. Peak peritoneal concentration was 40.0 +/- 14.5 micrograms/ml and peritoneal concentration at 24 hours after drug administration was 4.3 +/- 3.9 micrograms/ml. The median pharmacokinetic advantage (AUC peritoneal/AUC plasma) was 515 (range 22-1, 770). Grade 2 and 3 toxicities included 5 episodes of diarrhea; 3 of abdominal pain; 3 of ascites; 2 of alopecia; and 1 of neutropenia. We conclude that intraperitoneal docetaxel administration is well tolerated and provides a peritoneal pharmacokinetic advantage for the treatment of peritoneal dissemination.

PMID:
12402426
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center